0000950170-24-022659 | 10-K | XBRL Viewer | Verrica Pharmaceuticals INC

Debt - Summary of Composition of Debt (Detail) - Senior Loan Agreement [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Gross proceeds	$ 50,000
Accrued final payment fee	2,500
Unamortized debt discount and issuance costs	(9,626)
Total short-term debt, net	$ 42,874

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Related Party Transactions	12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 5—Related Party Transactions Prior to the completion of the initial public offering (“IPO”) of the Company’s common stock in June 2018, the Company was controlled by PBM VP Holdings, LLC (“PBM VP Holdings”) an affiliate of PBM Capital Group, LLC (“PBM”). Paul B. Manning, who is the Chairman and Chief Executive Officer of PBM and the current chairman of the Company’s Board of Directors, and certain entities affiliated with Mr. Manning, continue to be the Company’s largest shareholder on a collective basis. On December 2, 2015, the Company entered into a Services Agreement (the “SA”) with PBM. Pursuant to the terms of the SA, which had an initial term of twelve months (and was automatically renewable for successive monthly periods), PBM rendered advisory and consulting services to the Company. Services provided under the SA included certain business development, operations, technical, contract, accounting and back office support services. In consideration for these services, the Company was obligated to pay PBM a monthly management fee. On October 1, 2019, the SA was amended to reduce the monthly management fee to $5,000 as a result of a reduction in services provided by PBM. For each of the years ended December 31, 2023 and 2022, the Company incurred expenses under the SA of $60,000, of which $36,000 were included in general and administrative expenses, and $24,000 were included in research and development expenses. As of December 31, 2023, the Company had $10,000 of payables due to PBM and its affiliates. On September 8, 2022, the Company entered into a clinical service agreement with Clinical Enrollment LLC which is controlled by Bryan Manning, the son of Paul B. Manning, who is the current chairman of the Company's Board of Directors. Paul B. Manning along with certain entities affiliated with Mr. Manning, are the Company's largest stockholder on a collective basis. Pursuant to the clinical service agreement, Clinical Enrollment LLC may provide recruiting support services for the Company's VP-315 clinical trial. No fees were due under the agreement until a minimum number of patients are enrolled in the clinical trial by the vendor. Compensation of $30,000 was recognized during the year ended December 31, 2022 for the development and production fee of media, video, and web to support recruitment services. After meeting the minimum enrollments, compensation includes a $15,000 fee per eligible patient enrolled in the trial. Patient expenses of $0.4 million were incurred for the year ended December 31, 2023, all of which was classified as research and development expenses. As of December 31, 2023, the Company had $0.1 million of payables due to Clinical Enrollment LLC.

Related Party Transactions

12 Months Ended

Dec. 31, 2023

Related Party Transactions

Note 5—Related Party Transactions

Prior to the completion of the initial public offering (“IPO”) of the Company’s common stock in June 2018, the Company was controlled by PBM VP Holdings, LLC (“PBM VP Holdings”) an affiliate of PBM Capital Group, LLC (“PBM”). Paul B. Manning, who is the Chairman and Chief Executive Officer of PBM and the current chairman of the Company’s Board of Directors, and certain entities affiliated with Mr. Manning, continue to be the Company’s largest shareholder on a collective basis.

On December 2, 2015, the Company entered into a Services Agreement (the “SA”) with PBM. Pursuant to the terms of the SA, which had an initial term of twelve months (and was automatically renewable for successive monthly periods), PBM rendered advisory and consulting services to the Company. Services provided under the SA included certain business development, operations, technical, contract, accounting and back office support services. In consideration for these services, the Company was obligated to pay PBM a monthly management fee. On October 1, 2019, the SA was amended to reduce the monthly management fee to $5,000 as a result of a reduction in services provided by PBM.

For each of the years ended December 31, 2023 and 2022, the Company incurred expenses under the SA of $60,000, of which $36,000 were included in general and administrative expenses, and $24,000 were included in research and development expenses.

As of December 31, 2023, the Company had $10,000 of payables due to PBM and its affiliates.

On September 8, 2022, the Company entered into a clinical service agreement with Clinical Enrollment LLC which is controlled by Bryan Manning, the son of Paul B. Manning, who is the current chairman of the Company's Board of Directors. Paul B. Manning along with certain entities affiliated with Mr. Manning, are the Company's largest stockholder on a collective basis. Pursuant to the clinical service agreement, Clinical Enrollment LLC may provide recruiting support services for the Company's VP-315 clinical trial. No fees were due under the agreement until a minimum number of patients are enrolled in the clinical trial by the vendor. Compensation of $30,000 was recognized during the year ended December 31, 2022 for the development and production fee of media, video, and web to support recruitment services. After meeting the minimum enrollments, compensation includes a $15,000 fee per eligible patient enrolled in the trial. Patient expenses of $0.4 million were incurred for the year ended December 31, 2023, all of which was classified as research and development expenses. As of December 31, 2023, the Company had $0.1 million of payables due to Clinical Enrollment LLC.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Amortization ROU assets	$ 20	$ 0
Amortization ROU assets	23	4
Interest on lease liabilities	7	0
Total finance lease costs	30	4
Operating lease costs	282	369
Short-term lease costs	0	7
Total operating lease expense	$ 282	$ 376

Leases - Schedule of Weighted Average Remaining Term and Discount Rate (Detail)	Dec. 31, 2023
Leases [Abstract]
Operating lease,Weighted average remaining lease term	3 years 6 months 29 days
Operating lease,Weighted average discount rate	6.25%
Finance lease,Weighted average remaining lease term	4 years 3 months 7 days
Finance lease,Weighted average discount rate	7.87%

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	As of December 31, 2023		As of December 31, 2022
Gross to net reserves	$	5,357	$	—
Compensation and related costs		3,438		1,399
Clinical trials and drug development		2,767		974
Professional fees		1,423		58
Commercial-related costs		538		—
Other current liabilities		244		—
Machinery and equipment		93		224
Total accrued expenses and other current liabilities	$	13,860	$	2,655

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryovers	$ 37,167	$ 29,771
Sec. 174 Capitalization	5,150	2,465
Share-based compensation	4,690	3,704
Tax credits	3,081	2,615
Accrued compensation	803	345
Amortization	673	780
Lease liabilities	619	383
Other	2,122	70
Total deferred tax assets	54,305	40,133
Less valuation allowance	(53,684)	(39,732)
Deferred tax asset, net of valuation allowance	621	401
Deferred tax liabilities:
Right-of-use assets	(601)	(362)
Fixed assets	(20)	(39)
Total deferred tax liabilities	(621)	(401)
Net deferred tax assets	$ 0	$ 0

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 69,547	$ 34,273
Accounts receivable	4,248	0
Collaboration revenue receivable	0	388
Unbilled collaboration revenue	168	99
Inventory	1,022	0
Prepaid expenses and other assets	2,545	4,355
Total current assets	77,530	39,115
Property and equipment, net	1,052	3,887
Operating lease right-of-use asset	1,158	1,443
Finance lease right-of-use asset	1,405	0
Other non-current assets	452	276
Total assets	81,597	44,721
Current liabilities:
Accounts payable	2,464	507
Accrued expenses and other current liabilities	13,860	2,655
Operating lease liability	324	297
Financing lease liability	376	0
Total current liabilities	17,024	3,459
Operating lease liability	910	1,229
Financing lease liability	1,026	0
Long term debt	42,874	0
Total liabilities	61,834	4,688
Commitments and Contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 200,000,000 authorized; 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023 and 41,199,197 shares issued and 41,094,053 shares outstanding as of December 31, 2022	4	4
Treasury stock, at cost, 105,144 shares as of December 31, 2023 and 2022	0	0
Additional paid-in capital	250,207	203,482
Accumulated deficit	(230,448)	(163,453)
Total stockholders’ equity	19,763	40,033
Total liabilities and stockholders’ equity	$ 81,597	$ 44,721

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Feb. 23, 2023	Feb. 28, 2023	Jul. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, authorized				200,000,000	200,000,000
Common stock, par value				$ 0.0001	$ 0.0001
Number of common shares sold	750,000
Shares Issued, Price Per Share	$ 6.75
Pre Funded Warrant [Member]
Class of Stock [Line Items]
Warrant issued to purchase company's common stock	4,064,814	4,064,814		4,064,814
Warrant price (per share)	$ 6.7499	$ 6.7499		$ 0.0001
Underwritten Offering [Member]
Class of Stock [Line Items]
Number of common shares sold		750,000
Sale of stock consideration		$ 30.3
Shares Issued, Price Per Share		$ 6.75
Underwritten Offering [Member] \| Pre Funded Warrant [Member]
Class of Stock [Line Items]
Warrant issued to purchase company's common stock		4,064,814
Follow-on Public Offering [Member]
Class of Stock [Line Items]
Number of common shares sold			13,575,000

License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands			1 Months Ended					12 Months Ended
	Jul. 21, 2023	Mar. 17, 2021	May 31, 2022	Apr. 30, 2021	Feb. 28, 2021	Dec. 31, 2020	Aug. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
License And Collaboration Agreements [Line Items]
Research and development expense	$ 4,500							$ 20,295	$ 12,198
Ltyix [Member]
License And Collaboration Agreements [Line Items]
Payments upon achievements of milestone							$ 111,000
One time up front license fee			$ 1,000		$ 2,300						$ 300
Research and development expense									1,000	$ 2,300
Percentage of royalty income shared							50.00%
Torii Agreement [Member] \| Torii [Member]
License And Collaboration Agreements [Line Items]
Received payment				$ 11,500		$ 500
Payments upon achievements of milestone									50,000
Billed collaboration revenue								500	500
Unbilled collaboration revenue								$ 1,000	1,000
Torii Agreement [Member] \| Torii [Member] \| License Revenue [Member]
License And Collaboration Agreements [Line Items]
Milestone payment recognized									$ 8,000
Torii Agreement [Member] \| Torii [Member] \| Minimum [Member]
License And Collaboration Agreements [Line Items]
Mid Percentage of transfer price payments for supply of product net sales		30.00%
Torii Agreement [Member] \| Torii [Member] \| Maximum [Member]
License And Collaboration Agreements [Line Items]
Mid Percentage of transfer price payments for supply of product net sales		40.00%

Inventory - Schedule Of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 420	$ 0
Work in process	487	0
Finished goods	115	0
Total inventory	$ 1,022	$ 0

Leases - Schedule of Maturities of Operating and Finance Lease (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
Operating Lease, Year One	$ 390
Operating Lease, Year Two	372
Operating Lease, Year Three	366
Operating Lease, Year Four	247
Operating Lease, After Year Four	0
Operating Lease, Total lease payments	1,375
Less Operating Lease, imputed interest	(141)
Operating Lease, Lease liability	1,234
Finance Lease, Year One	470
Finance Lease, Year Two	402
Finance Lease, Year Three	343
Finance Lease, Year Four	324
Finance Lease, After Year Four	83
Finance Lease, Total lease payments	1,622
Less Finance Lease, imputed interest	(220)
Finance Lease, Lease liability	$ 1,402

Organization and Description of Business Operations

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business Operations

Note 1—Organization and Description of Business Operations

Verrica Pharmaceuticals Inc. (the “Company”) was formed on July 3, 2013 and is incorporated in the State of Delaware. The Company is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. On July 21, 2023, the U.S. Food and Drug Administration (“FDA”) approved YCANTH (formerly referred to as VP-102) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The Company launched commercial operations in August 2023.

Liquidity and Capital Resources

The Company has incurred substantial operating losses since inception and expects to continue to incur significant losses for the foreseeable future and may never become profitable. As of December 31, 2023, the Company had an accumulated deficit of $230.4 million. In July 2022, the Company sold 13,575,000 shares of common stock at a public offering price of $2.10 per share, resulting in cumulative net proceeds of $26.9 million after deducting underwriting discounts and commissions, and offering expenses. On February 23, 2023, the Company sold 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock were sold at a price of $6.75 per share and the pre-funded warrants were sold at a price of $6.7499 per pre-funded warrant, resulting in net proceeds of $30.3 million after deducting underwriting discounts and commissions, and offering expenses of approximately $2.3 million (see Note 8).

On July 26, 2023, the Company entered into a Credit Agreement which provides for up to $125.0 million in debt under a Loan Facility (as defined in Note 11). The Company borrowed $50.0 million under the Loan Facility on July 26, 2023, resulting in net proceeds of approximately $44.1 million after payment of certain fees and transaction related expenses. In addition, up to $25.0 million will be made available on or prior to June 30, 2024, up to $30.0 million will be made available on or prior to December 31, 2024, up to $10.0 million will be made available on or prior to March 31, 2025, and up to $10.0 million will be made available on or prior to June 30, 2025, in each case, subject to the Company's achievement of certain revenue targets. Amounts borrowed under the Loan Facility will mature on July 26, 2028.

The Company believes its cash, and cash equivalents of $69.5 million as of December 31, 2023 will be sufficient to support the Company’s planned operations into the second quarter of 2025.

Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 14,376	$ 4,985
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	11,796	3,525
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 2,580	$ 1,460

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Restricted Stock Awards Activities

The following table summarizes the activity related to the RSUs:


				Weighted Average
				Grant Date Fair
	Number of Shares			Value
Nonvested as of December 31, 2021 and December 31, 2022		425,000		$	11.68
Granted		698,000			7.58
Forfeited		—			—
Vested		(561,500	)		9.13
Nonvested as of December 31, 2023		561,500		$	9.13

Schedule of Stock Based Compensation Expense

Stock-based compensation expense, which includes expense for both employees and non-employees, has been reported in the Company’s statements of operations as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Selling, general and administrative	$	11,796	$	3,525
Research and development		2,580		1,460
Total stock-based compensation	$	14,376	$	4,985

Employee and Non-Employee Stock Options [Member]

Assumptions Used to Estimate Fair Value

The grant date fair value of employee and non-employee stock option awards is determined using the Black-Scholes option-pricing model. The following assumptions were used during the years ended December 31, 2023 and 2022 to estimate the fair value of employee and non-employee stock option awards:


	For the Year Ended December 31,
	2023		2022
Risk-free rate of interest	3.57% - 4.76%		1.67% - 4.36%
Expected term (years)	5.3 - 6.3		5.3 - 6.0
Expected stock price volatility	93.09% - 95.94%		86.58% - 95.10%
Dividend yield		—		—

Summary of Stock Option Activity

The following table summarizes the Company’s employee and non-employee stock option activity under the 2013 Plan and 2018 Plan for the years ended December 31, 2023 and 2022:


						Weighted average
				Weighted average		remaining contractual		Aggregate intrinsic
	Number of shares			exercise price		term (in years)		value
Outstanding as of December 31, 2021		3,443,817		$	10.05
Granted		1,137,936			6.86
Exercised		—			—
Forfeited and expired		(648,974	)		10.90
Outstanding as of December 31, 2022		3,932,779		$	8.99		7.3	$	173,604
Granted		1,760,836			6.38
Exercised		(8,000	)		0.90
Forfeited and expired		(120,000	)		5.52
Outstanding as of December 31, 2023		5,565,615		$	8.25		7.2	$	4,143,150
Options vested and exercisable as of December 31, 2023		3,081,357		$	9.07		5.9	$	1,810,191

Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Significant Accounting Policies

Note 2—Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s functional currency is the U.S. dollar.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience as well as other pertinent industry and regulatory authority information, results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and money market mutual funds.

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s deposits are in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.

Cash and cash equivalents at December 31, 2023 includes a cash deposit of $500,000 with Bank of America as required under the Commercial Credit Card Program with a balance equal to the outstanding credit limit on commercial credit cards.

Fair Value of Financial Instruments and Credit Risk

At December 31, 2023, the Company’s financial instruments included cash equivalents, accounts payable, accrued expenses and notes payable. The carrying amount of cash equivalents, accounts payable and accrued expenses approximated fair value, given their short-term nature. The carrying value of the Company's long term debt (Note 11) approximates fair value as the interest rate is reflective of current market rates on debt with similar terms and conditions.

Cash equivalents subject the Company to concentrations of credit risk. However, the Company invests its cash in accordance with a policy objective that seeks to ensure both liquidity and safety of principal. The policy limits investments to instruments issued by the U.S. government, certain SEC registered money market funds that invest only in U.S. government obligations and various other low-risk liquid investment options, and places restrictions on portfolio maturity terms.

Accounts receivable, trade subjects the Company to concentrations of credit risk as all of the Company's revenue is from sales of a single product, YCANTH (VP-102), to one pharmaceutical wholesale/distributor.

Accounts Receivable, Trade

Trade receivables, net of allowance for doubtful accounts related to YCANTH (VP-102) sales, which are recorded in net accounts receivable on the balance sheet, were $4.2 million as of December 31, 2023. As of December 31, 2023, the Company had no allowance for doubtful accounts. An allowance for doubtful accounts is determined based on the Company's assessment of the creditworthiness and financial condition of its customers, aging of receivables, as well as the general economic environment. Any allowance would reduce the net receivables to the amount that is expected to be collected. Current payment terms for YCANTH (VP-102) are 60 days from the shipment date.

Inventory

The Company values inventory at the lower of cost or net realizable value. Inventory cost is determined using the specific identification method. The Company regularly reviews its inventory quantities and, when appropriate, records a provision for obsolete and excess inventory to derive the new cost basis, which takes into account the Company’s sales forecast and corresponding expiry dates. The Company has not recognized a provision for obsolete and excess inventory as of December 31, 2023.

On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum contagiosum and began capitalizing inventory purchases of saleable product from certain suppliers. Prior to FDA approval, all product purchased from such suppliers was included as a component of research and development expense, as the Company was unable to assert that the inventory had future economic benefit until YCANTH (VP-102) received FDA approval. Pursuant to the supply agreement (Note 7), the Company purchased

and included in research and development expenses approximately $4.5 million of raw cantharidin and processed active pharmaceutical ingredient ("API"). The raw cantharidin and processed API is sufficient to produce approximately 14 million finished drug product applicators to be used for commercially saleable product and other product candidates. In addition, the Company purchased other components and services related to YCANTH (VP-102) for commercially saleable product and included approximately $1.2 million in research and development expenses prior to FDA approval. As a result, cost of product revenue related to YCANTH (VP-102) will initially reflect a lower average per unit cost of materials over approximately the next six months as previously expensed inventory is utilized for commercial production and sold to customers. If the Company were to have included those costs previously expensed as a component of cost of product revenue, the Company’s cost of product revenue for twelve months ended December 31, 2023 would have been $0.5 million.

Property and Equipment

Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight line method over the expected useful lives of the assets, after the assets are placed in service.

Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred.

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. If the estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount, an impairment loss would be recognized if the carrying value of the asset exceeds its fair value. Fair value is generally determined using discounted cash flows. The Company recognized a $2.6 million impairment loss on disposal of the assembly and packaging line during the year ended December 31, 2023 (see Note 3). No impairment losses were recorded during the year ended December 31, 2022. The Company generally uses the following depreciable lives for its major classifications of property and equipment:


Description		Useful lives
Machinery and equipment		3 - 5 years
Office furniture and fixtures and equipment		3 years
Leasehold improvements		Lease Term
Automobiles		3 years

Debt Issuance Costs

Debt issuance costs incurred in connection with the Loan Facility (Note 11) are amortized to interest expense over the term of the financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.

Revenue

Product Revenue, Net

The Company recognizes revenue from sales of a single product, YCANTH (the “Product”) in accordance with ASC Topic 606 – Revenue from Contracts with Customers. YCANTH (VP-102) became available for commercial sale and shipment to patients with a prescription in the United States in the year ended December 31, 2023. The Company sells the Product to one customer, a pharmaceutical wholesaler/distributor (the “Customer”) who in turn sells the Product directly to clinics, hospitals, and federal healthcare programs. Revenue is recognized as the Product is physically delivered to the Customer.

Gross product sales are reduced by corresponding gross-to-net (“GTN”) estimates using the expected value method, resulting in the Company’s reported “Product revenue, net” in the accompanying consolidated statements of operations. Product revenue, net reflects the amount the Company ultimately expects to realize in net cash proceeds, taking into account the current period gross sales and related cash receipts and the subsequent cash disbursements on these sales that the Company estimates for the various GTN categories discussed below. The GTN estimates are

based upon information received from external sources, such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period, in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, co-pay assistance and distribution, data, and group purchasing organizations ("GPO") administrative fees may be materially above or below the amount estimated. Variance between actual amounts and estimated amounts may result in prospective adjustments to reported net product revenue.

Each of the GTN estimate categories are discussed below:

Product Returns Allowances: The Customer is contractually permitted to return purchased Product in certain circumstances. The Company estimates expected returns based on the Company’s review of similar products in the industry while also using the limited sales history. As historical data for returns of the Product becomes available over time, the Company will utilize historical return rates of the Product in making its estimates. Returned Product is typically destroyed, since substantially all returns are due to expiry and cannot be resold.

Government Chargebacks: The Product is subject to pricing limits under certain federal government programs, including Medicare and the 340B drug pricing program. Qualifying entities (the “End-Users”) purchase the Product from the Customer at their applicable qualifying discounted price. The chargeback amount the Company incurs represents the difference between the Company’s contractual sales price to the Customer and the end-user’s applicable discounted purchase price under the government program.

Medicaid Rebates: The Product is subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with the Product is covered under Medicaid, resulting in a discounted price for the Product under the applicable Medicaid program. The Medicaid rebate accrual calculations require the Company to project the magnitude of its sales, by state, that will be subject to these rebates.

Patient Assistance: The Company offers a voluntary co-pay patient assistance program intended to provide financial assistance to eligible patients with a prescription drug co-payment required by payors and coupon programs for cash payors. The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with YCANTH (VP-102) that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.

Distribution, Data, and GPO Administrative Fees: Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of the Company’s products for various commercial services including contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of the Company’s applicable sales.

Collaboration Revenues

The Company has generated collaboration revenue through its licensing and collaboration arrangements. The terms of the arrangements typically include payments to the Company of one or more of the following: nonrefundable, up-front license fees: regulatory and commercial milestone payments; payments for manufacturing supply services; materials shipped to support development; and royalties on net sales of licensed products.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps:

(i)

identification of the promised goods or services in the contract;

(ii)

determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;

(iii)

measurement of the transaction price, including the constraint on variable consideration;

(iv)

allocation of the transaction price to the performance obligations; and

(v)

recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company’s revenue arrangements may include the following:

Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of an agreement that includes regulatory or commercial milestone payments, the Company evaluates whether each milestone is considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At each reporting period, the Company assesses the probability of achievement of each milestone under its current agreements.

Royalties: If the Company is entitled to receive sales-based royalties from its collaborator, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, provided the reported sales are reliably measurable, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Manufacturing Supply and Research Services: Arrangements that include a promise for supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If not, the supply services are recognized as collaboration revenue as the Company provides the services.

The Company receives payments from its licensees based on schedules established in each contract. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. See Note 13 for a full discussion of the Company’s collaboration arrangements.

Cost of Product Revenue

Cost of product revenue includes the cost of inventory sold, which includes direct manufacturing, production and packaging materials for YCANTH (VP-102) sales. Prior to FDA approval in July 2023, the Company expensed approximately $0.2 million in costs associated with the manufacturing of YCANTH (VP-102) as a component of research and development expense. Therefore, these costs are not included in cost of product revenue.

Advertising Expense

Advertising expenses, comprised primarily of print and digital assets, social media and internet advertising as well as search engine marketing, are expensed as incurred and are included in selling, general, and administrative expenses. For the year end December 31, 2023, advertising expenses were approximately $3.5 million.

Research and Development Costs

The Company’s research and development expenses consist primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and equity-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

Fair Value Measurement

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Stock-Based Compensation

The Company accounts for stock-based compensation awards in accordance with ASC 718, Compensation –Stock Compensation. The Company uses the Black-Scholes option-pricing model to value its stock option awards. For stock-based awards granted to employees, non-employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option award and recognizes compensation expense on a straight-line basis over the vesting period of the award.

The use of the Black‑Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk‑free interest rates, and, for grants prior to the Company’s IPO, the value of the common stock. The expected term of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company historically has been a private-company and lacked company-specific historical and implied volatility information. Therefore, prior to the year ended December 31, 2023, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies in addition to the volatility of the Company's stock. For the year ended December 31, 2023, volatility is based solely on the Company's stock. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

The fair value of restricted stock awards are based on the closing price of the Company’s common stock on the grant date.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

Net Loss Per Share

Net loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period including pre-funded warrants to purchase 4,064,814 shares of common stock that were issued in an underwritten offering in February 2023 (Note 8). The pre-funded warrants to purchase common stock are included in the calculation of basic and diluted net loss per share as the exercise price of $0.0001 per share is non-substantive and is virtually assured. Diluted net loss per share excludes the potential impact of common stock options and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company’s net loss. Since the Company had a net loss in each of the periods presented, basic and dilutive net loss per common share are the same.

The table below provides potential shares outstanding that were not included in the computation of diluted net loss per common share, as the inclusion of these securities would have been anti-dilutive:


	As of December 31,
	2023		2022
Shares issuable upon exercise of stock options		5,565,615		3,932,779
Non-vested shares under restricted stock grants		561,500		425,000
Shares issuable upon exercise of warrants pursuant to debt financing		518,551		—
Total		6,645,666		4,357,779

Recently Adopted Accounting Pronouncements

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for the Company on January 1, 2024, and is not expected to have a material impact on the Company’s financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses, Measurement of Credit Losses on Financial Instruments (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance was effective for the Company as of January 1, 2023 and did not have a material impact on the Company's financial statements and related disclosures.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]
Total revenue	$ 5,124	$ 9,032
Operating expenses:
Selling, general and administrative	47,305	17,405
Research and development	20,295	12,198
Loss on disposal of assets	2,537	0
Cost of product revenue	289	0
Cost of collaboration revenue	457	725
Total operating expenses	70,883	30,328
Loss from operations	(65,759)	(21,296)
Other (expense) income :
Interest income	2,740	476
Interest expense	(3,962)	(2,172)
Loss on extinguishment of debt	0	(1,437)
Other expense	(14)	(58)
Total other expense, net	$ (1,236)	$ (3,191)
Net loss per share, basic	$ (1.48)	$ (0.72)
Net loss per share, diluted	$ (1.48)	$ (0.72)
Weighted-average common shares outstanding, basic	45,342,451	34,163,437
Weighted-average common shares outstanding, diluted	45,342,451	34,163,437
Net loss	$ (66,995)	$ (24,487)
Other comprehensive gain:
Unrealized gain on marketable securities	0	29
Comprehensive loss	(66,995)	(24,458)
Product [Member]
Revenues [Abstract]
Total revenue	4,658	0
Collaboration [Member]
Revenues [Abstract]
Total revenue	$ 466	$ 9,032

Debt (Tables)

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Summary of Composition of Debt

The following table summarizes the composition of debt as reflected on the balance sheet as of December 31, 2023 (in thousands):


Gross proceeds	$	50,000
Accrued final payment fee		2,500
Unamortized debt discount and issuance costs		(9,626	)
Total long-term debt, net	$	42,874

Property and Equipment

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 3—Property and Equipment

Property and equipment, net consists of (in thousands):


	As of
	December 31,
	2023			2022
Machinery and equipment	$	1,543		$	1,392
Office equipment		326			301
Office furniture and fixtures		303			303
Leasehold improvements		54			54
Construction in process		-			2,536
		2,226			4,586
Accumulated depreciation		(1,174	)		(699	)
Total property and equipment, net	$	1,052		$	3,887

Depreciation expense for both the years ended December 31, 2023 and 2022 was $0.5 million.

The Company had recorded an asset classified as construction in process associated with the construction of a product assembly and packaging line that was expected to be placed into service for commercial manufacturing upon regulatory product approval. However, it was determined that the asset was impaired due to the high cost

required to upgrade the line as a result of changes in product assembly. As a result, the Company recognized a $2.5 million loss on the disposal of the asset included on the statement of operations and comprehensive loss during the year ended December 31, 2023.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Note 9—Stock-Based Compensation

In June 2018, the Board adopted and approved the 2018 Equity Incentive Plan (the “2018 Plan”), which amended and restated the Company’s prior 2013 Equity Incentive Plan (the “2013 Plan”) and became effective in connection with the IPO. Prior to the effectiveness of the 2018 Plan, the 2013 Plan provided for the grant of share-based awards to employees, directors and consultants of the Company. As a result of the effectiveness of the 2018 Plan, no further grants may be made under the 2013 Plan.

The 2018 Plan provides for the grant of incentive stock options to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of stock awards to employees, including officers, consultants and directors. The 2018 Plan also provides for the grant of performance-based cash awards to employees, including officers, consultants and directors. The Company initially reserved 3,738,199 shares of common stock for issuance under the 2018 Plan, which is the sum of (1) 2,198,198 new shares, plus (2) the number of shares reserved for issuance under the 2013 Plan at the time the 2018 Plan became effective, plus (3) any shares subject to outstanding stock options or other stock awards that would have otherwise returned to the 2013 Plan (such as upon the expiration or termination of a stock award prior to exercise). The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 each year, for a period of ten years, from January 1, 2019 through January 1, 2028, by 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. As of December 31, 2023, 2,419,919 shares were available for grant under the 2018 Plan.

Stock Options

The Company’s employee and non-employee stock options generally vest as follows: 25% after 12 months of continuous services and the remaining 75% on a ratable basis over a 36-month period from 12 months after the grant

date. Stock options granted during the year ended December 31, 2023 have a maximum contractual term of 10 years. The stock options are subject to time vesting requirements through 2026, are nontransferable, and have term expiration dates set to expire through 2033.


	For the Year Ended December 31,
	2023		2022
Risk-free rate of interest	3.57% - 4.76%		1.67% - 4.36%
Expected term (years)	5.3 - 6.3		5.3 - 6.0
Expected stock price volatility	93.09% - 95.94%		86.58% - 95.10%
Dividend yield		—		—

The following table summarizes the Company’s employee and non-employee stock option activity under the 2013 Plan and 2018 Plan for the years ended December 31, 2023 and 2022:


						Weighted average
				Weighted average		remaining contractual		Aggregate intrinsic
	Number of shares			exercise price		term (in years)		value
Outstanding as of December 31, 2021		3,443,817		$	10.05
Granted		1,137,936			6.86
Exercised		—			—
Forfeited and expired		(648,974	)		10.90
Outstanding as of December 31, 2022		3,932,779		$	8.99		7.3	$	173,604
Granted		1,760,836			6.38
Exercised		(8,000	)		0.90
Forfeited and expired		(120,000	)		5.52
Outstanding as of December 31, 2023		5,565,615		$	8.25		7.2	$	4,143,150
Options vested and exercisable as of December 31, 2023		3,081,357		$	9.07		5.9	$	1,810,191

The aggregate intrinsic value in the above table is calculated as the difference between fair market value of the Company’s common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for the employee and non-employee stock options granted during the years ended December 31, 2023 and 2022 was $5.07 and $5.23, respectively. As of December 31, 2023, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $12.0 million, which the Company expects to recognize over a weighted-average period of 2.6 years.

Restricted Stock Units

In November 2019 and August 2020 the Company granted 300,000 and 250,000 restricted stock units ("RSU"), respectively, to its executive officers of which 125,000 were forfeited. Half of the remaining RSUs vested upon receipt of regulatory approval of YCANTH (VP-102) for the treatment of molluscum on July 21, 2023 (the “Approval Date”) and the other half will vest on July 21, 2024 subject to the holders’ continuous service through such date.

In March 2023, the Company granted 698,000 RSUs, half of which vested upon the first commercial sale of YCANTH (VP-102) on August 24, 2023 (the “First Sale Date”) and half of which will vest on August 24, 2024 subject to the holders’ continuous service through such date.

Compensation expense of $8.8 million was recognized in the Company’s statements of operations for the year ended December 31, 2023 related to the vested RSUs based on the fair market value at the date of grant. As of December 31, 2023, the remaining unrecognized compensation expense related to the RSUs was $1.5 million, which

the Company expects to recognize over a weighted average service period of 0.4 years now that vesting of these awards is probable.

The following table summarizes the activity related to the RSUs:


				Weighted Average
				Grant Date Fair
	Number of Shares			Value
Nonvested as of December 31, 2021 and December 31, 2022		425,000		$	11.68
Granted		698,000			7.58
Forfeited		—			—
Vested		(561,500	)		9.13
Nonvested as of December 31, 2023		561,500		$	9.13

Stock-based compensation expense, which includes expense for both employees and non-employees, has been reported in the Company’s statements of operations as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Selling, general and administrative	$	11,796	$	3,525
Research and development		2,580		1,460
Total stock-based compensation	$	14,376	$	4,985

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

Differences between the provision (benefit) for income taxes and income taxes at the statutory federal income tax rate are as follows (in thousands):


	For the Year Ended December 31,
	2023			2022
Tax computed at statutory federal income tax rate	$	(14,069	)	$	(5,142	)
State taxes, net of federal benefit		(1,547	)		(955	)
Permanent items		1,063			251
R&D credits		(466	)		(235	)
Change in tax rate		482			4,637
Other		585			127
Change in valuation allowance		13,952			1,317
Income tax provision (benefit)	$	—		$	—

Schedule of Components of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):


	As of December 31,
	2023			2022
Deferred tax assets:
Net operating loss carryovers	$	37,167		$	29,771
Sec. 174 capitalization		5,150			2,465
Share-based compensation		4,690			3,704
Tax credits		3,081			2,615
Accrued compensation		803			345
Amortization		673			780
Lease liabilities		619			383
Other		2,122			70
Total deferred tax assets		54,305			40,133
Less valuation allowance		(53,684	)		(39,732	)
Deferred tax asset, net of valuation allowance		621			401
Deferred tax liabilities:
Right-of-use assets		(601	)		(362	)
Fixed assets		(20	)		(39	)
Total deferred tax liabilities		(621	)		(401	)
Net deferred tax assets	$	—		$	—

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 530	$ 454
Loss on disposal of assets	$ (2,537)	$ 0

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Note 12–Income Taxes

There is no provision for income taxes as the Company has incurred operating losses since inception and maintains a full valuation allowance against its deferred tax assets.

Differences between the provision (benefit) for income taxes and income taxes at the statutory federal income tax rate are as follows (in thousands):


	For the Year Ended December 31,
	2023			2022
Tax computed at statutory federal income tax rate	$	(14,069	)	$	(5,142	)
State taxes, net of federal benefit		(1,547	)		(955	)
Permanent items		1,063			251
R&D credits		(466	)		(235	)
Change in tax rate		482			4,637
Other		585			127
Change in valuation allowance		13,952			1,317
Income tax provision (benefit)	$	—		$	—

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):


	As of December 31,
	2023			2022
Deferred tax assets:
Net operating loss carryovers	$	37,167		$	29,771
Sec. 174 capitalization		5,150			2,465
Share-based compensation		4,690			3,704
Tax credits		3,081			2,615
Accrued compensation		803			345
Amortization		673			780
Lease liabilities		619			383
Other		2,122			70
Total deferred tax assets		54,305			40,133
Less valuation allowance		(53,684	)		(39,732	)
Deferred tax asset, net of valuation allowance		621			401
Deferred tax liabilities:
Right-of-use assets		(601	)		(362	)
Fixed assets		(20	)		(39	)
Total deferred tax liabilities		(621	)		(401	)
Net deferred tax assets	$	—		$	—

The Company has determined, based upon all available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax asset.

As of December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $149.6 million and $152.1 million, respectively. The federal net operating loss carryforwards included in the foregoing totals that were generated prior to 2018 (federal of approximately $6.9 million) will begin to expire, if not utilized, by 2033. Under the 2017 federal income tax law changes, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. As of December 31, 2023, the Company had federal and state research and development carryforwards of $3.1 million. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss and tax credit carryforwards may be limited. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception.

The Company will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve months.

The 2017 and subsequent federal and state tax years for the Company remain open for the assessment of income taxes.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Finance lease cost:
Amortization ROU assets	$	23	$	4
Interest on lease liabilities		7		—
Total finance lease costs	$	30	$	4
Operating lease:
Operating lease costs	$	282	$	369
Short-term lease costs		—		7
Total operating lease expense	$	282	$	376

Schedule of Maturities of Operating and Finance Leases

Maturities of the Company’s operating leases, excluding short-term leases, as of December 31, 2023 are as follows (in thousands):


	Operating			Finance
2024	$	390		$	470
2025		372			402
2026		366			343
2027		247			324
Thereafter		—			83
Total lease payments		1,375			1,622
Less imputed interest		(141	)		(220	)
Lease liability	$	1,234		$	1,402

Schedule of Weighted Average Remaining Term and Discount Rate

The weighted average remaining lease term and discount rates for the Company's leases as of December 31, 2023 are as follows:



	Operating			Finance
Weighted average remaining lease term (years)		3.58			4.27
Weighted average discount rate		6.25	%		7.87	%

Inventory (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule Of Inventory

Inventory consisted of the following (in thousands):


	December 31,		December 31,
	2023		2022
Raw materials	$	420	$	—
Work in process		487		—
Finished goods		115		—
Total inventory	$	1,022	$	—

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

Note 10—Leases

The Company leases 11,201 square feet of office space located in West Chester, Pennsylvania that serves as the Company’s headquarters. The initial term expires on September 1, 2027. Base rent over the initial term is approximately $2.4 million, and the Company is also responsible for its share of the landlord’s operating expenses.

The Company leases office space in Scotch Plains, New Jersey under an agreement classified as an operating lease, which commenced on May 1, 2022 and expires on April 30, 2025. Base rent over the initial term is approximately $104,000 per year. During the year ended December 31, 2022, the Company recognized a right-of-use asset of $99,000 and a lease liability of $95,000.

The Company entered into a fleet program to provided vehicles for its sales force. The vehicles are leased for a term of 52 months and classified as finance leases. During the year ended December 31, 2023, the Company recognized a right-of-use asset of $1.4 million and a lease liability of $1.4 million related to these finance leases.

The components of lease expense are as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Finance lease cost:
Amortization ROU assets	$	23	$	4
Interest on lease liabilities		7		—
Total finance lease costs	$	30	$	4
Operating lease:
Operating lease costs	$	282	$	369
Short-term lease costs		—		7
Total operating lease expense	$	282	$	376

Maturities of the Company’s operating leases, excluding short-term leases, as of December 31, 2023 are as follows (in thousands):


	Operating			Finance
2024	$	390		$	470
2025		372			402
2026		366			343
2027		247			324
Thereafter		—			83
Total lease payments		1,375			1,622
Less imputed interest		(141	)		(220	)
Lease liability	$	1,234		$	1,402

The weighted average remaining lease term and discount rates for the Company's leases as of December 31, 2023 are as follows:



	Operating			Finance
Weighted average remaining lease term (years)		3.58			4.27
Weighted average discount rate		6.25	%		7.87	%

Stockholders' Equity - Summary of Company's Outstanding Warrants (Detail) - $ / shares	Dec. 31, 2023	Feb. 28, 2023	Feb. 23, 2023
Pre-funded warrants pursuant to common stock issuance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants	4,064,814	4,064,814	4,064,814
Exercise Price	$ 0.0001	$ 6.7499	$ 6.7499
Warrants issued with OrbiMed debt facility [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants	518,551
Exercise Price	$ 6.0264
Expiration Date	Jul. 25, 2033

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (66,995)	$ (24,487)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	14,376	4,985
Amortization of premiums on marketable securities	0	108
Depreciation expense	530	454
Noncash interest expense	810	383
Loss on disposal of fixed assets	2,537	0
Loss on extinguishment of debt	0	1,437
Gain on operating lease termination	0	6
Amortization of operating lease right-of-use asset	286	264
Amortization of finance lease right-of-use asset	20	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets	587	(456)
Accounts payable	2,201	(338)
Accounts receivable	(3,860)	0
Unbilled receivable	(69)	(487)
Accrued expenses and other current liabilities	11,291	(255)
Operating lease liability	(291)	(264)
Net cash used in operating activities	(38,577)	(18,650)
Cash flows from investing activities
Sales and maturities of marketable securities	0	59,008
Purchases of marketable securities	0	(4,485)
Purchases of property and equipment	(362)	(302)
Deposits	0	(180)
Net cash (used in) provided by investing activities	(362)	54,041
Cash flows from financing activities
Proceeds from exercise of stock options	7	0
Proceeds from issuance of debt, net of issuance costs	44,105	0
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs	30,300	26,901
Equity issuance costs	(177)	0
Repayment of debt	0	(43,750)
Debt issuance costs	0	(17)
Repayment of financing lease	(23)	(4)
Net cash provided by (used in) financing activities	74,213	(16,870)
Net increase in cash and cash equivalents	35,274	18,521
Cash and cash equivalents at the beginning of the year	34,273	15,752
Cash and cash equivalents at the end of the year	69,547	34,273
Supplemental disclosures
Cash paid for interest	3,152	1,789
Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases in accounts payable or accrued expenses and other current liabilities at year end	93	167
Change in unrealized loss on marketable securities	0	29
Fair Value of warrants from debt financing	2,041	0
Right-of-use asset obtained in exchange for lease obligation	$ 1,428	$ 99

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Treasury Stock, Common [Member]	Accumulated Other Comprehensive income (Loss) [Member]
Beginning Balance at Dec. 31, 2021	$ 32,605	$ 3	$ 171,597	$ (138,966)		$ (29)
Beginning Balance (shares) at Dec. 31, 2021		27,624,197			105,144
Stock-based compensation	4,985		4,985
Issuance of common stock and pre-funded warrants, net of issuance costs	26,901	$ 1	26,900
Issuance of common stock and pre-funded warrants, net of issuance costs (shares)		13,575,000
Fair Value of warrants from debt financing	0
Net loss	(24,487)			(24,487)
Unrealized gain on marketable securities	29					$ 29
Ending Balance at Dec. 31, 2022	40,033	$ 4	203,482	(163,453)
Ending Balance (shares) at Dec. 31, 2022		41,199,197			105,144
Stock-based compensation	14,376		14,376
Issuance of common stock and pre-funded warrants, net of issuance costs	30,301		30,301
Issuance of common stock and pre-funded warrants, net of issuance costs (shares)		750,000
Fair Value of warrants from debt financing	2,041		2,041
Restricted stock vested		561,500
Exercise of stock options	7		7
Exercise of stock options		8,000
Net loss	(66,995)			(66,995)
Unrealized gain on marketable securities	0
Ending Balance at Dec. 31, 2023	$ 19,763	$ 4	$ 250,207	$ (230,448)
Ending Balance (shares) at Dec. 31, 2023		42,518,697			105,144

Income Taxes - Reconciliation of Income Taxes at U.S. Federal Statutory Rate to Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Tax computed at statutory federal income tax rate	$ (14,069)	$ (5,142)
State taxes, net of federal benefit	(1,547)	(955)
Permanent items	1,063	251
R&D credits	(466)	(235)
Change in tax rate	482	4,637
Other	585	127
Change in valuation allowance	13,952	1,317
Income tax provision (benefit)	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	42,518,697	41,199,197
Common stock, shares outstanding	42,413,553	41,094,053
Treasury Stock, Common, Shares	105,144	105,144

Commitments and Contingencies

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7—Commitments and Contingencies

Litigation

On June 6, 2022, plaintiff Kranthi Gorlamari (“Plaintiff” filed a putative class action complaint captioned Gorlamari v. Verrica Pharmaceuticals Inc., et al., in the U.S. District Court for the Eastern District of Pennsylvania against us and certain of our current and former officers and directors (“Defendants”). On January 12, 2023, the Plaintiff filed an amended complaint alleging that Defendants violated federal securities laws by, among other things, failing to disclose certain manufacturing deficiencies at the facility where our contract manufacturer produced bulk solution for the YCANTH (VP-102) drug device and that such deficiencies posed a risk to the prospects for regulatory approval of YCANTH (VP-102) for the treatment of molluscum. The amended complaint seeks unspecified compensatory damages and other relief on behalf of Plaintiff and all other persons and entities which purchased or otherwise acquired our securities between May 19, 2021 and May 24, 2022 (the “Putative Class Period”).

On January 12, 2024, the Court granted in part and denied in part Defendants’ motion to dismiss the amended complaint. The Court held that Plaintiff’s claims relating to statements made in May and June 2021 were sufficiently pled, but dismissed Plaintiff’s claims relating to all other statements made during the Putative Class Period. On January 26, 2024, Plaintiff filed a second amended complaint in an attempt to cure certain of the deficiencies identified in the January 12, 2024 ruling. Defendants have until March 11, 2024 to answer or file a motion against the second amended complaint.

The Company is also involved in ordinary, routine legal proceedings that are not considered by management to be material. In the opinion of Company counsel and management, the ultimate liabilities resulting from such legal proceedings will not materially affect the financial position of the Company or its results of operations or cash flows.

Supply Agreement and Purchase Order

On July 16, 2018, the Company entered into a supply agreement with a supplier of crude cantharidin material. All executed purchase orders for crude cantharidin in the ordinary course of business are expected to be covered under the terms of the supply agreement. Pursuant to the supply agreement, the supplier has agreed that it will not supply cantharidin, any beetles or other raw material from which cantharidin is derived to any other customer in North America, subject to specified minimum annual purchase orders and forecasts by the Company. The supply agreement had an initial five-year term, and now renews for successive annual periods absent termination by either party in accordance with the terms of the supply agreement. Each party also has the right to terminate the supply agreement for other customary reasons such as material breach or bankruptcy.

In both 2023 and 2022, the Company executed respective purchase orders pursuant to which the Company agreed to purchase $0.7 million of crude cantharidin material and made prepayments of $0.7 million in each year against the purchase orders. The Company received the shipment for the 2022 purchase, however, the 2023 purchase has yet to be received. As of December 31, 2023 and 2022, the balance sheet reflects prepaid expense of $0.7 million and $1.5 million, respectively.

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Schedule of Depreciable Lives of Property and Equipment

The Company generally uses the following depreciable lives for its major classifications of property and equipment:


Description		Useful lives
Machinery and equipment		3 - 5 years
Office furniture and fixtures and equipment		3 years
Leasehold improvements		Lease Term
Automobiles		3 years

Schedule of Potential Shares Outstanding not Included in Computation of Diluted Net Loss Per Common Share


	As of December 31,
	2023		2022
Shares issuable upon exercise of stock options		5,565,615		3,932,779
Non-vested shares under restricted stock grants		561,500		425,000
Shares issuable upon exercise of warrants pursuant to debt financing		518,551		—
Total		6,645,666		4,357,779

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2023	Feb. 23, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Trading Symbol	VRCA
Entity Interactive Data Current	Yes
Entity Registrant Name	Verrica Pharmaceuticals Inc.
Entity Central Index Key	0001660334
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 152.4
Entity Common Stock, Shares Outstanding		42,418,553
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity File Number	001-38529
Entity Tax Identification Number	46-3137900
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Annual Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	44 West Gay Street
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	West Chester
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19380
City Area Code	484
Local Phone Number	453-3300
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2024 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.
Auditor Name	KPMG LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	185
Document Financial Statement Error Correction [Flag]	false

Stock-Based Compensation - Assumptions Used to Estimate Fair Value Employee Stock Options (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Dividend yield	0.00%	0.00%
Employee and Non-Employee Stock Options [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Risk-free rate of interest, minimum	3.57%	1.67%
Risk-free rate of interest, maximum	4.76%	4.36%
Expected stock price volatility, minimum	93.09%	86.58%
Expected stock price volatility, maximum	95.94%	95.10%
Employee and Non-Employee Stock Options [Member] \| Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (years)	5 years 3 months 18 days	5 years 3 months 18 days
Employee and Non-Employee Stock Options [Member] \| Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (years)	6 years 3 months 18 days	6 years

Organization and Description of Business Operations - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended
	Jul. 26, 2023	Feb. 23, 2023	Jul. 31, 2022	Dec. 31, 2023	Feb. 28, 2023	Dec. 31, 2022
Description Of Business [Line Items]
Number of common shares sold		750,000
Shares issued		750,000
Shares Issued, Price Per Share		$ 6.75
Offering expenses		$ 2,300
Accumulated deficit				$ (230,448)		$ (163,453)
Cash and cash equivalents				$ 69,547		$ 34,273
Term A Loan [Member]
Description Of Business [Line Items]
Net proceeds from issuance	$ 44,100
Line of credit	50,000
Credit facility, maximum borrowing capacity	$ 125,000
Loans, maturity date	Jul. 26, 2028
Available On Or Prior To June 30, 2024 [Member]
Description Of Business [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 25,000
Available On Or Prior To December 31, 2024 [Member]
Description Of Business [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	30,000
Available On Or Prior To March 31, 2025 [Member]
Description Of Business [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	10,000
Available On Or Prior To June 30, 2025 [Member]
Description Of Business [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 10,000
Pre funded warrant [Member]
Description Of Business [Line Items]
Net proceeds from issuance		$ 30,300
Class of Warrant or Right, Outstanding		4,064,814		4,064,814	4,064,814
Warrant price (per share)		$ 6.7499		$ 0.0001	$ 6.7499
Follow-on Public Offering [Member]
Description Of Business [Line Items]
Number of common shares sold			13,575,000
Share price			$ 2.1
Net proceeds from issuance			$ 26,900
Shares issued			13,575,000

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product Liability Contingency [Line Items]
Prepaid expense	$ 0.7	$ 1.5
Crude Cantharidin Material [Member]
Product Liability Contingency [Line Items]
Purchase agreement term	5 years
Purchase Commitment	$ 0.7
Purchase commitment prepayment		$ 0.7

Stock-Based Compensation - Schedule of Restricted Stock Awards Activities (Detail) - Restricted Stock Units (RSUs) [Member] - $ / shares	1 Months Ended		12 Months Ended
	Aug. 31, 2020	Nov. 30, 2019	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested, Number of Shares, Beginning Balance			425,000
Non-vested, Number of Shares, Granted			698,000
Non-vested, Number of shares, Forfeited	(125,000)	(125,000)	0
Non-vested, Number of shares, Vested			(561,500)
Non-vested, Number of Shares, Ending Balance			561,500
Non-vested, Weighted Average Grant Date Fair Value, Beginning Balance			$ 11.68
Nonvested, Weighted Average Grant Date Fair Value, Granted			7.58
Nonvested, Weighted Average Grant Date Fair Value, Forfeited			0
Non-vested, Weighted average grant date fair value, Vested			9.13
Non-vested, Weighted Average Grant Date Fair Value, Ending Balance			$ 9.13

Property and Equipment - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,226	$ 4,586
Accumulated depreciation	(1,174)	(699)
Total property and equipment, net	1,052	3,887
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,543	1,392
Office Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	326	301
Office Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	303	303
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	54	54
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 0	$ 2,536

Leases - Additional Information (Detail)	12 Months Ended
Leases - Additional Information (Detail)	Dec. 31, 2023 USD ($) ft²	Dec. 31, 2022 USD ($)
Lessee Lease Description [Line Items]
Lease expiration date	Sep. 01, 2027
Operating lease right of use asset	$ 1,158,000	$ 1,443,000
Finance lease right-of-use asset	1,405,000	0
Finance lease liability	1,402,000
Operating lease liability	1,234,000
Other income (expense)	$ (14,000)	(58,000)
Operating lease, remaining lease term	3 years 6 months 29 days
Finance lease, remaining lease term	4 years 3 months 7 days
Operating lease, discount rate	6.25%
Finance lease, discount rate	7.87%
Pennsylvania [Member]
Lessee Lease Description [Line Items]
Area of office space for lease \| ft²	11,201
NEW JERSEY
Lessee Lease Description [Line Items]
Lease agreement commencement date	May 01, 2022
Lease expiration date	Apr. 30, 2025
Operating lease, base rent	$ 104,000
Operating lease right of use asset		99,000
Operating lease liability		$ 95,000
Automobile Fleet Lease Program [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use asset	1,400,000
Finance lease liability	$ 1,400,000
Term of lease	52 months
Landlord's Operating Expense [Member]
Lessee Lease Description [Line Items]
Operating lease, base rent	$ 2,400,000

Debt

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Debt

Note 11–Debt

On July 11, 2022, the Company voluntarily repaid its previous debt facility (the “Mezzanine Loan Agreement”) in full in the amount of $43.8 million, inclusive of principal amount of debt, the final payment fee, and accrued interest, and satisfied all of the Company’s outstanding debt obligations. The Company did not incur any prepayment penalties in connection with the repayment of the debt. The prepayment was made in full using restricted cash of $40.0 million, as well as cash on hand of $3.8 million for the final payment fee. For the year ended December 31, 2022, the Company recognized a $1.4 million loss on debt extinguishment which consisted of non-cash unamortized debt issuance costs.

For the year ended December 31, 2022, the Company recognized interest expense related to the terminated facility of $2.2 million, of which $0.6 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of the final payment fee.

On July 26, 2023 (the “Closing Date”), the Company entered into a Credit Agreement (the “Credit Agreement”), by and between the Company, as borrower, and OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “Initial Lender”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $125.0 million (the “Loan Facility”), of which $50.0 million was made available on the Closing Date ("Initial Commitment Amount"), up to $25.0 million will be made available on or prior to June 30, 2024, up to $30.0 million will be made available on or prior to December 31, 2024, up to $10.0 million will be made available on or prior to March 31, 2025, and up to $10.0 million will be made available on or prior to June 30, 2025, in each case, subject to the Company's achievement of certain revenue targets. Amounts borrowed under the Loan Facility will mature on July 26, 2028. On July 26, 2023, the Company closed on the Initial Commitment Amount, resulting in net proceeds to the Company of approximately $44.1 million after payment of certain fees and transaction related expenses of $5.9 million. During the term of the Loan Facility, interest payable in cash by the Company shall accrue on any outstanding balance due under the Loan Facility at a rate per annum equal to the higher of (x) the SOFR rate (which is the forward-looking term rate for a one-month tenor based on the secured overnight financing rate administered by the CME Group Benchmark Administration Limited) and (y) 4.00% plus, in either case, 8.00%. During an event of default, any outstanding amount under the Loan Facility will bear interest at a rate of 4.00% in excess of the otherwise applicable rate of interest. The Company paid or will pay certain fees with respect to the Loan Facility, including an upfront fee, an unused fee on the undrawn portion of the Loan Facility, an administration fee, a prepayment premium and an exit fee, as well as certain other fees and expenses of the Administrative Agent and the Lenders.

On the Closing Date, the Company also issued the Initial Lender warrants to purchase up to 518,551 shares of the Company’s common stock, at an exercise price of $6.0264 per share, which have a term of 10 years from the

issuance date. The warrants were deemed to be classified as equity per the guidance ASC 815 Derivatives and Hedging. The proceeds from the debt transaction were allocated among the two instruments based on their relative fair values. The relative fair value of the warrants was determined to be $2.0 million and the fair value was determined to be $2.4 million based on the black-scholes valuation technique and the key assumptions used were as follows: (i) an expected term of 10 years, (ii) an expected volatility of 94.86%, (iii) a risk free rate of 3.86% and (iv) no estimated dividend yield.

On each of December 20, 2023 and January 31, 2024, the Company entered into an amendment to the Credit Agreement in order to extend a deadline for a specified regulatory milestone. For the second amendment on January 31, 2024, the Company paid an upfront amendment fee of $250,000 and agreed to make an additional payment of $250,000 if a specified regulatory milestone is not achieved by a specified date.

The Loan Facility is classified as non-current debt at issuance as the Company does not currently intend to repay amounts borrowed under the Loan Facility prior to the maturity date of July 26, 2028 and believes that the probability of any acceleration of the Loan Facility is not probable at December 31, 2023. The Company has incurred debt discount and issuance costs of $10.4 million, that are classified as a contra-liability on the balance sheet. The debt discount and issuance costs consists of $5.9 million paid in cash during the year ended December 31, 2023 and the final payment fee of $2.5 million, classified as a long-term liability and the fair value of the warrants of $2.0 million, classified as equity on the condensed balance sheet.

For the year ended December 31, 2023, the Company recognized interest expense related to the Credit Agreement of $4.0 million, of which $3.2 million was interest on the term loan and $0.8 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of the final payment fee.

The following table summarizes the composition of debt as reflected on the balance sheet as of December 31, 2023 (in thousands):

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Significant Accounting Policies - Additional Information (Detail)		12 Months Ended
	Jul. 21, 2023 USD ($)	Dec. 31, 2023 USD ($) Segment $ / shares shares	Dec. 31, 2022 USD ($)	Feb. 28, 2023 shares	Feb. 23, 2023 shares
Significant Accounting Policies [Line Items]
Number of operating segments \| Segment		1
Financial instruments with off-balance sheet risk of loss		$ 0
Bank cash deposits		500,000,000
Accounts receivable		4,248,000	$ 0
Allowance for doubtful accounts		$ 0
Basic exercise price \| $ / shares		$ 0.0001
Diluted exercise price \| $ / shares		$ 0.0001
Research and development expense	$ 4,500,000	$ 20,295,000	12,198,000
Advertising expense		3,500,000
Cost of product revenue		500,000
Finished goods		115,000	0
Impairment losses		$ 2,600,000	$ 0
Expected dividend yield		0.00%	0.00%
Expected dividend payments		$ 0
YCANTH [Member]
Significant Accounting Policies [Line Items]
Research and development expense	1,200,000
Finished goods	14,000,000
FDA
Significant Accounting Policies [Line Items]
Research and development expense	$ 200,000
Pre Funded Warrant [Member]
Significant Accounting Policies [Line Items]
Warrant issued to purchase company's common stock \| shares		4,064,814		4,064,814	4,064,814

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Federal and state research and development carryforwards			$ 3,100,000
Equity ownership period	3 years
Unrecognized tax benefits, income tax penalties and interest accrued	$ 0	$ 0
Unrecognized tax benefits, income tax penalties and interest expense	$ 0	$ 0
Minimum [Member] \| Equity Ownership [Member]
Operating Loss Carryforwards [Line Items]
Ownership percentage	50.00%
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 149,600,000			$ 6,900,000
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 152,100,000
Net Operating Loss Carryforwards Generated in 2016 and 2017 [Member]
Operating Loss Carryforwards [Line Items]
Federal and state net operating loss carryforwards, expiration date	2033

Stockholders' Equity

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

Stockholders' Equity

Note 8—Stockholders’ Equity

Common Stock

The Company had authorized 200,000,000 shares of common stock, $0.0001 par value per share, as of December 31, 2023 and December 31, 2022. Each share of common stock is entitled to one vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Board.

Underwritten Public Offering

In February 2023, the Company closed an underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock were sold at a price of $6.75 per share and the pre-funded warrants were sold at a price of $6.7499 per pre-funded warrant, resulting in net proceeds of $30.3 million after deducting underwriting discounts and commissions, and offering expense. The pre-funded warrants will not expire and are exercisable in cash or by means of a cashless exercise.

Warrants

The following table summarizes the Company’s outstanding warrants:


	As of December 31, 2023
	Number of warrants		Exercise Price		Expiration Date
Pre-funded warrants pursuant to common stock issuance		4,064,814	$	0.0001	No expiration
Warrants issued with OrbiMed debt facility		518,551	$	6.0264	7/25/2033

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Company's Outstanding Warrants

The following table summarizes the Company’s outstanding warrants:


	As of December 31, 2023
	Number of warrants		Exercise Price		Expiration Date
Pre-funded warrants pursuant to common stock issuance		4,064,814	$	0.0001	No expiration
Warrants issued with OrbiMed debt facility		518,551	$	6.0264	7/25/2033

Related Party Transactions - Additional Information (Detail) - USD ($)				12 Months Ended
	Jul. 21, 2023	Oct. 01, 2019	Dec. 02, 2015	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Selling, general and administrative				$ 47,305,000	$ 17,405,000
Research and development	$ 4,500,000			20,295,000	12,198,000
Fee Per Eligible Patient				15,000
Research and development expense	$ 4,500,000			20,295,000	12,198,000
PBM Capital Group, LLC [Member]
Related Party Transaction [Line Items]
Services agreement initial term			12 months
Expenses incurred under services agreement				60,000	60,000
Selling, general and administrative				36,000	36,000
Research and development				24,000	24,000
Due to related party				10,000
Research and development expense				24,000	24,000
PBM Capital Group, LLC [Member] \| Amended Service Agreement [Member]
Related Party Transaction [Line Items]
Monthly management fee payable		$ 5,000,000
Clinical Enrollment LLC [Member]
Related Party Transaction [Line Items]
Research and development				100,000
Development Fee Compensation					$ 30,000
Research and development expense				100,000
Research and Development Expense [Member] \| Clinical Enrollment LLC [Member]
Related Party Transaction [Line Items]
Patient expenses				$ 400,000

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2013 and 2018 Equity Incentive Plan [Member] - Employee and Non-Employee Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Outstanding Beginning Balance	3,932,779	3,443,817
Number of shares, Granted	1,760,836	1,137,936
Number of shares, Exercised	(8,000)	0
Number of shares, Forfeited and Expired	(120,000)	(648,974)
Number of shares, Outstanding Ending Balance	5,565,615	3,932,779
Number of shares, Options vested and exercisable Ending Balance	3,081,357
Weighted average exercise price, Outstanding Beginning Balance	$ 8.99	$ 10.05
Weighted average exercise price, Granted	6.38	6.86
Weighted average exercise price, Exercised	0.9	0
Weighted average exercise price, Forfeited and Expired	5.52	10.9
Weighted average exercise price, Outstanding Ending Balance	8.25	$ 8.99
Weighted average exercise price, Options vested and exercisable Ending Balance	$ 9.07
Weighted average remaining contractual life (in years), Outstanding	7 years 2 months 12 days	7 years 3 months 18 days
Weighted average remaining contractual life (in years), Options vested and exercisable	5 years 10 months 24 days
Aggregate intrinsic value, Outstanding	$ 4,143,150	$ 173,604
Aggregate intrinsic value, Options vested and exercisable Ending Balance	$ 1,810,191

Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Gross to net reserves	$ 5,357	$ 0
Compensation and related costs	3,438	1,399
Clinical trials and drug development	2,767	974
Professional fees	1,423	58
Commercial-related costs	538	0
Other current liabilities	244	0
Machinery and equipment	93	224
Total accrued expenses and other current liabilities	$ 13,860	$ 2,655

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 6—Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	As of December 31, 2023		As of December 31, 2022
Gross to net reserves	$	5,357	$	—
Compensation and related costs		3,438		1,399
Clinical trials and drug development		2,767		974
Professional fees		1,423		58
Commercial-related costs		538		—
Other current liabilities		244		—
Machinery and equipment		93		224
Total accrued expenses and other current liabilities	$	13,860	$	2,655

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Segments

Cash and Cash Equivalents

Fair Value of Financial Instruments and Credit Risk

Accounts Receivable, Trade

Inventory

Property and Equipment


Description		Useful lives
Machinery and equipment		3 - 5 years
Office furniture and fixtures and equipment		3 years
Leasehold improvements		Lease Term
Automobiles		3 years

Debt Issuance Costs

Revenue

Product Revenue, Net

Each of the GTN estimate categories are discussed below:

Collaboration Revenues

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps:

(i)

identification of the promised goods or services in the contract;

(ii)

determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;

(iii)

measurement of the transaction price, including the constraint on variable consideration;

(iv)

allocation of the transaction price to the performance obligations; and

(v)

recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company’s revenue arrangements may include the following:

Cost of Product Revenue

Advertising Expense

Research and Development Costs

Fair Value Measurement

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Share Based Compensation

Stock-Based Compensation

The fair value of restricted stock awards are based on the closing price of the Company’s common stock on the grant date.

Income Taxes

Net Loss Per Share


	As of December 31,
	2023		2022
Shares issuable upon exercise of stock options		5,565,615		3,932,779
Non-vested shares under restricted stock grants		561,500		425,000
Shares issuable upon exercise of warrants pursuant to debt financing		518,551		—
Total		6,645,666		4,357,779

Recently Adopted Accounting Pronouncements

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net consists of (in thousands):


	As of
	December 31,
	2023			2022
Machinery and equipment	$	1,543		$	1,392
Office equipment		326			301
Office furniture and fixtures		303			303
Leasehold improvements		54			54
Construction in process		-			2,536
		2,226			4,586
Accumulated depreciation		(1,174	)		(699	)
Total property and equipment, net	$	1,052		$	3,887

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions					1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 21, 2024	Aug. 24, 2023	Jul. 21, 2023	Feb. 23, 2023	Aug. 31, 2020	Nov. 30, 2019	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued				750,000
Employee and Non-Employee Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted contractual term								10 years
Stock option vesting term, description								through 2026
Stock options expiration term, description								through 2033
Weighted average grant date fair value per share								$ 5.07	$ 5.23
Total unrecognized compensation								$ 12.0
Weighted-average stock option recognize period								2 years 7 months 6 days
Employee and Non-Employee Stock Options [Member] \| Share-based Compensation Award, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock subject to vesting (as a percent)								25.00%
Stock vesting period								12 months
Employee and Non-Employee Stock Options [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock subject to vesting (as a percent)								75.00%
Stock vesting period								12 months
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average stock option recognize period								4 months 24 days
Non-vested, Number of shares, Vested								561,500
Stock repurchased and retired per share								$ 9.13
Number of Shares, Granted								698,000
Non-vested, Number of shares, Forfeited					(125,000)	(125,000)		0
Compensation expense								$ 8.8
Remaining unrecognized compensation related to nonvested restricted stock units								$ 1.5
Restricted Stock Units (RSUs) [Member] \| Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted					250,000	300,000	698,000
Restricted Stock Units (RSUs) [Member] \| New Drug Application [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock subject to vesting (as a percent)		50.00%	50.00%
Restricted Stock Units (RSUs) [Member] \| YCANTH [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock subject to vesting (as a percent)		50.00%
Restricted Stock Units (RSUs) [Member] \| Forecast [Member] \| One Year Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock subject to vesting (as a percent)	50.00%
2018 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares reserved for issuance								3,738,199
Shares issued								2,198,198
Number of years reserved share increase								10 years
Annual Increase in number of common shares from January 1, 2019 through January 1, 2028								4.00%
Shares available for grant								2,419,919

Inventory

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventory

Note 4 —Inventory

Upon FDA approval of YCANTH (VP-102) for the treatment of molluscum contagiosum on July 21, 2023, the Company began capitalizing the purchases of saleable inventory of YCANTH (VP-102) from suppliers. Inventory consisted of the following (in thousands):


	December 31,		December 31,
	2023		2022
Raw materials	$	420	$	—
Work in process		487		—
Finished goods		115		—
Total inventory	$	1,022	$	—

Debt - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jan. 31, 2024	Jul. 26, 2023	Jul. 11, 2022	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Cash, cash equivalents and marketable securities			$ 40,000
Fair value of the warrants		$ 2,400
Addition to upfront amendment fee				$ 250,000
Expected dividend yield				0.00%	0.00%
Repayment of debt			43,800	$ 0	$ 43,750
Final payment fee			$ 3,800
Loss on extinguishment of debt				0	(1,437)
Subsequent Event [Member]
Debt Instrument [Line Items]
Upfront amendment fee	$ 250,000
Common Stock [Member]
Debt Instrument [Line Items]
Warrant issued to purchase company's common stock		518,551
Warrant price (per share)		$ 6.0264
Warrant term		10 years
Warrant [Member]
Debt Instrument [Line Items]
Fair value of the warrants		$ 2,000
Expected term (years)		10 years
Expected volatility		94.86%
Risk free rate		3.86%
Expected dividend yield		0.00%
Loan Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 125,000
Initial Commitment Amount		50,000
Net proceeds after payment of certain fees and transaction related expenses		44,100
Transaction related expenses		$ 5,900
Loans, maturity date		Jul. 26, 2028
SOFR
Debt Instrument [Line Items]
Interest rate (as a percent)		4.00%
Loans, interest rate		8.00%
Interest rate (as a percent)		4.00%
Available On Or Prior To June 30, 2024 [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		$ 25,000
Available On Or Prior To June 30, 2024 [Member] \| Loan Facility [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		25,000
Available On Or Prior To December 31, 2024 [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		30,000
Available On Or Prior To December 31, 2024 [Member] \| Loan Facility [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		30,000
Available On Or Prior To March 31, 2025 [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		10,000
Available On Or Prior To March 31, 2025 [Member] \| Loan Facility [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		10,000
Available On Or Prior To June 30, 2025 [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		10,000
Available On Or Prior To June 30, 2025 [Member] \| Loan Facility [Member]
Debt Instrument [Line Items]
Remaining Commitment Amount		10,000
Term A Loan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 125,000
Loans, maturity date		Jul. 26, 2028
Line of credit		$ 50,000
Senior Loan Agreement [Member]
Debt Instrument [Line Items]
Debt discount and issuance costs		10,400		5,900
Final payment fee		$ 2,000
Unamortized debt discount and issuance costs				9,626
Interest expense				4,000	2,200
Interest on term loan				3,200
Non-cash interest expense				800	$ 600
Senior Loan Agreement [Member] \| Contra-Liability [Member]
Debt Instrument [Line Items]
Final payment fee				$ 2,500

Significant Accounting Policies - Schedule of Potential Shares Outstanding not Included in Computation of Diluted Net Loss Per Common Share (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities that could potentially dilute basic earnings per share	6,645,666	4,357,779
Shares issuable upon exercise of stock options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities that could potentially dilute basic earnings per share	5,565,615	3,932,779
Non-vested shares under restricted stock grants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities that could potentially dilute basic earnings per share	561,500	425,000
Shares issuable upon exercise of warrants pursuant to debt financing [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities that could potentially dilute basic earnings per share	518,551	0

License And Collaboration Agreements

12 Months Ended

Dec. 31, 2023

License And Collaboration Agreements [Abstract]

License and Collaboration Agreements

Note 13—License and Collaboration Agreements

On March 17, 2021, the Company entered into a collaboration and license agreement (the “Torii Agreement”) with Torii, pursuant to which the Company granted Torii an exclusive license to develop and commercialize the Company’s product candidates that contain a topical formulation of cantharidin for the treatment of molluscum contagiosum and common warts in Japan, including YCANTH (VP-102). Additionally, the Company granted Torii a right of first negotiation with respect to additional indications for the licensed products and certain additional products for use in the licensed field, in each case in Japan.

Pursuant to the Torii Agreement, the Company received payments from Torii of $0.5 million in December 2020 and $11.5 million in April 2021. On July 25, 2022 Torii dosed the first patient in its Phase 3 trial of YCANTH (VP-102) (referred to as TO-208 in Japan) for molluscum contagiosum in Japan, triggering an $8.0 million milestone payment recognized as collaboration revenue in the statement of operations for the year period ended December 31, 2022. Additionally, the Company is entitled to receive from Torii an additional $50 million in aggregate payments from Torii contingent on achievement of specified development, regulatory, and sales milestones, in addition to tiered transfer price payments for supply of product in the percentage range of the mid-30’s to the mid-40’s of net sales. The transfer payments shall be payable, on a product-by-product basis, beginning on the first commercial sale of such product and ending on the latest of (a) expiration of the last-to-expire valid claim contained in certain licensed patents in Japan that cover such product, (b) expiration of regulatory exclusivity for the first indication for such product in Japan, and, (c) (i) with respect to the first product, ten years after first commercial sale of such product, and, (ii) with respect to any other product, the later of (x) ten years after first commercial sale of the first product and (y) five years after first commercial sale of such product.

The Torii Agreement expires on a product-by-product basis upon expiration of Torii’s obligation under the agreement to make transfer price payments for such product. Torii has the right to terminate the agreement upon specified prior written notice to us. Additionally, either party may terminate the agreement in the event of an uncured material breach of the agreement by, or insolvency of, the other party. The Company may terminate the agreement in the event that Torii commences a legal action challenging the validity, enforceability or scope of any licensed patents.

On March 7, 2022, the Company executed a Clinical Supply Agreement with Torii, whereby the Company will supply product to Torii for use in clinical trials and other development activities. The Company recognized billed and unbilled collaboration revenue of $0.5 million and $1.0 million for the years ended December 31, 2023 and 2022, respectively related to supplies and development activity pursuant to this agreement.

In August 2020, the Company entered into an exclusive license agreement with Lytix Biopharma AS (“Lytix”) for the use of licensed technology to research, develop, manufacture, have manufactured, use, sell, have sold, offer for sale, import, and otherwise commercialize products for use in all malignant and pre-malignant dermatological indications, other than metastatic melanoma and metastatic Merkel cell carcinoma (the” Lytix Agreement”). As part of the Lytix Agreement, the Company paid Lytix a one-time up-front fee of $0.3 million in 2020. In addition, in May 2022 and February 2021, the Company paid Lytix a one-time $1.0 million and $2.3 million payment, respectively upon the achievement by Lytix of a regulatory milestone. The $1.0 and $2.3 million payments were recognized in research and development expense in the statement of operations for the years ended December 31, 2022 and 2021, respectively. The Company is also obligated to pay up to $111.0 million contingent on achievement of specified development, regulatory, and sales milestones, as well as tiered royalties based on worldwide annual net sales ranging in the low double digits to the mid-teens, subject to certain customary reductions. The Company’s obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of the expiration or abandonment of the last to expire licensed patent covering VP-315 anywhere in the world and expiration of regulatory exclusivity for VP-315 in such country. Additionally, all upfront fees and milestone-based payments received by the Company from a sublicensee will be treated as net sales and will be subject to the royalty payment obligations under the Lytix Agreement, and all royalties received by the Company from a sublicensee shall be shared with Lytix at a rate that is initially 50% but decreases based on the stage of development of VP-315 at the time such sublicense is granted.

Significant Accounting Policies - Schedule of Depreciable Lives of Property and Equipment (Detail)	Dec. 31, 2023
Machinery and Equipment [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Lives	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Lives	5 years
Office Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Lives	3 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	us-gaap:UsefulLifeTermOfLeaseMember
Automobiles [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Lives	3 years